Dive deeper

Open any topic for the full explanation, tables, clinical checkpoints, and references.

Full-length video Where can I learn more about what happens after a skin-cancer diagnosis?

A complete visual guide

Watch the full explanation on YouTube A complete visual review with the supporting clinical context.
What exactly was diagnosed?

First, Confirm Exactly What Was Diagnosed

Start with the pathology report—not the appearance of the spot before biopsy.

Useful questions include:

  • Is the diagnosis basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma, or another tumor?
  • Is it in situ or invasive?
  • Was a specific subtype or growth pattern identified?
  • Did the sample include enough depth to answer the staging question?
  • Are there features such as poor differentiation, perineural invasion, ulceration, or greater depth?
  • Does the clinical lesion seem larger or different from what the sample captured?1–4

A biopsy is a sample. It may remove the visible lesion, but that does not automatically mean the complete microscopic tumor was removed. Heterogeneous BCC can contain an aggressive component not present in the initial sample, and a superficial sample can understate cSCC invasion or melanoma depth.1,3,5–7

If the diagnosis is ambiguous, unexpected, or does not fit the clinical picture, dermatopathology review or a deeper sample may be appropriate before treatment is locked.

Which features change the risk?

Next, Identify the Features That Change Risk

The diagnosis name is the beginning, not the entire plan.

For BCC and cSCC, location, size, clinical borders, recurrence, biopsy subtype, depth, nerve involvement, prior radiation, and immune status can change the treatment pathway.1,2,8

For melanoma, Breslow thickness and ulceration influence excision margin, sentinel-node discussion, stage, and possible systemic treatment.3,4

Risk and stage are related but different. Risk stratification helps choose local treatment. Staging asks how far disease has extended. A higher-risk tumor does not mean that spread has already occurred; it means the team should be more deliberate about margin control, nodes, imaging, or follow-up.

How should treatment match the diagnosis and risk?

Then, Match Treatment to the Actual Problem

Possible treatment paths include:

  • Mohs surgery when complete mapped margins, recurrence, poorly defined extension, tissue preservation, or high-stakes anatomy matter;
  • standard excision for many primary, well-defined tumors when an appropriate margin can be removed safely;
  • curettage, topical therapy, or another simpler local treatment for selected superficial or lower-risk tumors;
  • radiation when surgery is not feasible or is declined, or after surgery in selected higher-risk situations;
  • systemic or multidisciplinary care for locally advanced, node-positive, metastatic, or selected high-risk disease.1–4,8–10

Ask why the proposed treatment fits this diagnosis and risk, and how its margins or treatment response will be assessed. No option should be chosen from a cure-rate advertisement alone.

How should I plan timing and repair?

Plan the Timeline and the Repair

Most skin cancers require timely care, but the correct timeline is not identical for every tumor. Rapid growth, pain, numbness, weakness, aggressive pathology, immune suppression, threatened function, palpable nodes, or suspected spread should accelerate coordination.2–4,8

The treatment timeline is individualized because cancer type, risk features, symptoms, site, and patient factors determine how quickly care should proceed.

A planned short interval to obtain pathology, coordinate medicines, or assemble the right team is different from an unexplained delay.

For surgery, the repair should be discussed before treatment but finalized after the true cancer-free wound is known. Options can include direct closure, a flap, a graft, natural healing, delayed repair, or collaboration with another surgeon.11

What should I bring to the treatment visit?

Questions to Bring to Your Visit

  1. What exact diagnosis and subtype did the biopsy show?
  2. Which features make this lower or higher risk?
  3. Is the sample deep and representative enough?
  4. Do I need imaging, lymph-node evaluation, or a pathology second opinion?
  5. What treatments are medically reasonable, and why?
  6. How will the margins be assessed?
  7. How urgent is treatment, and what should happen while I wait?
  8. What repair is likely, and who should perform it?
  9. What follow-up will I need after treatment?
What does the diagnosis change next?

What the Diagnosis Changes Next

What the Diagnosis Changes Next
DiagnosisImmediate planning questionMargin or staging issue
Basal cell carcinomaIs it low risk or does site, recurrence, border, or subtype favor Mohs?Complete margin mapping matters most when hidden extension would change the repair.
Cutaneous squamous cell carcinomaWhich features make it low, high, or very high risk?High-risk disease may require complete margin assessment, nodal examination, imaging, or adjuvant discussion.
MelanomaWhat are the Breslow depth, ulceration, and stage?The plan may include permanent pathology, margin-controlled surgery in selected sites, and sentinel-node discussion.
Rare tumorIs the diagnosis secure and is the biopsy deep enough?Expert pathology, tumor-specific staging, and a specialty team may be more important than a generic margin number.

Repair planning should use the clearance strategy, final defect, location, function, and the patient's priorities—not the biopsy photograph alone.

What does the evidence say about diagnosis and treatment?

Evidence by the Numbers

Evidence by the NumbersThe biopsy is the first map, not always the whole map

The biopsy is the first map, not always the whole map

18% overall; 28% of initially nonaggressive biopsies

Population
Two retrospective basal-cell-carcinoma series with different denominators
Outcome
One series found subtype disagreement in 18% of all biopsy-specimen comparisons; another found an aggressive component at Mohs in 28% of tumors whose biopsy had appeared nonaggressive
Time horizon
Biopsy compared with the later complete specimen

What it means: The treatment plan should use the biopsy, the examination, and the final margin information together.

Limitations: These are separate findings, not the endpoints of one range. The studies used different populations and methods, so the percentages should not be combined or copied to every cancer or biopsy technique.

References: 5, 6

Frequently asked questions after a skin-cancer diagnosis

Frequently Asked Questions

Does skin cancer always mean surgery?

No. Surgery is the primary treatment for many tumors, but selected low-risk lesions can be treated with simpler local methods, and radiation or systemic therapy can serve important roles.1–4

Should I panic if the appointment is not tomorrow?

No. Ask for a defined timeline based on diagnosis and risk. Call promptly if the lesion is rapidly changing or if you develop pain, numbness, weakness, bleeding, or another new concerning feature.

Do I need a full-body skin examination?

Often, because one skin cancer increases the chance of additional lesions and because the treatment decision benefits from the full clinical context. The timing and extent depend on the diagnosis and patient.

Can the pathology diagnosis be reviewed?

Yes. Review can be useful when the diagnosis is rare, ambiguous, high consequence, or discordant with the clinical picture.

Will the biopsy scar be removed during treatment?

Often the biopsy site lies within the treatment area, but the final operation is planned around the true tumor and margin strategy—not around the scar alone.

Who reviewed and authored this next-steps guide?
Portrait of Dr. Thomas L.H. Hocker

About the Author

Dr. Thomas L.H. Hocker is a Harvard- and Mayo Clinic-trained, triple board-certified dermatologist, Mohs surgeon, and dermatopathologist. He is the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health and an Iron Surgeon lecturer at the American Society for Dermatologic Surgery. His work focuses on Mohs surgery for melanoma, complex and rare skin tumors, and aesthetic reconstruction after skin-cancer treatment. He co-authored the best-selling textbook Review of Dermatology and created Skin Trust to give patients and clinicians free access to clear, current, evidence-based education.

Read Dr. Hocker's background and mission

Dr. Hocker earned his bachelor's degree with honors from Yale University, where he was inducted into Phi Beta Kappa. As a Winston Churchill Scholar, he then studied at the University of Cambridge and earned an M.Phil. in Organic Chemistry. He received his M.D. with honors from Harvard Medical School, where his research focused on melanoma genetics. He completed dermatology residency at Mayo Clinic, a dermatopathology fellowship at the University of Michigan, and a Mohs micrographic and reconstructive surgery fellowship at Mayo Clinic. He is board-certified in Dermatology, Dermatopathology, and Mohs Micrographic Surgery.

Dr. Hocker serves as the Founding Director of Dermatologic Surgery at the UMKC School of Medicine and University Health. He is an internationally invited lecturer and speaker who teaches about Mohs surgery for melanoma, complex and rare tumors, dermatopathology, and aesthetic reconstruction after skin-cancer treatment. He has also been selected as an Iron Surgeon lecturer by the American Society for Dermatologic Surgery. He is the co-author of Review of Dermatology, a best-selling dermatology review textbook, and he continues to teach and mentor medical students, residents, and physicians.

Skin Trust exists because Dr. Hocker believes access to excellent medical knowledge should not depend on geography, wealth, or proximity to a major academic center. After training at several of the world's leading institutions, he sees that education as both a gift and a responsibility: to translate current evidence, expert judgment, and hard-won clinical experience into guidance that patients, families, and clinicians can actually use.

The mission is to increase awareness, reduce avoidable suffering, and give every person equal access to trustworthy, up-to-date information that can help them make the best decisions for their life. Skin Trust also extends Dr. Hocker's lifelong commitment to teaching, writing, and mentoring medical students and residents as they build lives and careers of purpose and service.

For Dr. Hocker, this work is also an expression of faith. He regards the opportunities to learn at Yale, Cambridge, Harvard, Mayo Clinic, and the University of Michigan as blessings from God. Teaching, writing, mentoring, and building Skin Trust are ways to pay those blessings forward in service to patients, learners, and the broader community. His faith is the personal motivation to do this work carefully, generously, and with integrity; it is not a condition of using or benefiting from this free resource.

View Review of Dermatology Read Dr. Hocker's full biography
Where should I go next in the Patient Journey?

Next Steps in the Patient Journey

Continue to the guide for your diagnosis or the treatment question you are facing.

Continue with the question that fits you now

References for this next-steps guide

References

  1. National Comprehensive Cancer Network. Basal Cell Skin Cancer. Version 2.2026.
  2. National Comprehensive Cancer Network. Squamous Cell Skin Cancer. Updated March 17, 2026.
  3. National Comprehensive Cancer Network. Melanoma: Cutaneous. Updated April 17, 2026.
  4. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines for primary cutaneous melanoma. J Am Acad Dermatol. 2019. PMID: 30392755.
  5. Moon D, Randall G, Higgins S, Sutton AV, Wysong A. BCC subtype misclassification. Dermatol Surg. 2021. PMID: 33905389.
  6. Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for BCC subtyping. J Am Acad Dermatol. 2012. PMID: 21798620.
  7. Ahmadi O, Das M, Hajarizadeh B, Mathy JA. Impact of shave biopsy on melanoma management. Ann Surg Oncol. 2021. PMID: 33782802.
  8. Stevens JS, Murad F, Smile TD, et al. Validation of NCCN cSCC risk stratification. JAMA Dermatol. 2023.
  9. Wehner MR. Keratinocyte carcinoma. JAMA. 2025.
  10. Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023.
  11. Chen CL, et al. Multisociety guideline for reconstruction after skin-cancer resection. Facial Plast Surg Aesthet Med. 2021.